Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Progress of Mild Alzheimer's Disease in Participants on Solanezumab Versus Placebo (EXPEDITION 3)

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Eli Lilly and Company
ClinicalTrials.gov Identifier:
NCT01900665
First received: July 12, 2013
Last updated: November 30, 2016
Last verified: November 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is ongoing, but not recruiting participants.
  Estimated Study Completion Date: February 2017
  Primary Completion Date: October 2016 (Final data collection date for primary outcome measure)